Outcomes Among Patients in Brazil Receiving Palbociclib Combinations for HR+/HER2- MBC

Breast Cancer Clinical Trial

Official title:

TREATMENT PATTERNS AND CLINICAL OUTCOMES AMONG PATIENTS IN BRAZIL RECEIVING PALBOCICLIB COMBINATIONS FOR HR+/HER2- ADVANCED/METASTATIC BREAST CANCER IN REAL WORLD SETTINGS

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05505175
• Other study ID #: A5481168
• Secondary ID: IRIS Brazil
• Status: Completed
• Start date: May 30, 2022
• Est. completion date: May 2, 2023

Study information

• Verified date: May 2023
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The objective of this study is to describe patient demographics, clinical characteristics, treatment patterns and clinical outcomes of adult female patients who have received palbociclib combination treatments as first line therapy, regardless of combination partner and labelled use in real world settings across Brazil.

Description:

The primary objective of this real world study is to describe patient demographics, clinical characteristics, treatment patterns and clinical outcomes of adult female patients who have received palbociclib combination treatments as first line therapy, regardless of combination partner and labelled use.

Primary Objectives

• To describe the demographic and clinical characteristics of patients who have received palbociclib combination treatments in line with locally approved indications.

• To describe adjuvant therapies received for their treatment of early or locally advanced breast cancer (Stages 0-IIIa).

• To describe treatments received in the advanced/metastatic setting, before and after palbociclib combination use.

• To describe dosing and dose changes, interruptions, delays, and discontinuations associated with palbociclib use in clinical practice.

• To describe supportive therapies received by patients while receiving palbociclib combination treatments.

• To determine the following outcome in overall population and defined subgroups for patients who had received palbociclib combination treatment for at least 6 months:

• Progression-free survival;

• Objective response rate (ORR);

• Proportion of patients alive.

Exploratory Objectives

• To evaluate progression-free survival (PFS) associated with palbociclib combination treatments after 1 and 2 years following Palbociclib combination treatment.

This study will be conducted as a retrospective medical record review of patients who have received palbociclib combination treatments as first line treatment regardless of combination. The study will comprise of a medical record review conducted in Brazil. The study design is similar to a previously conducted RWE IRIS Global study previously conducted in multiple other countries (protocol no. A5481090) .

Data collection will be online via electronic data capture using electronic case report form (eCRF). Each physician will be asked to select all the medical records of approximately 5-20 patients per site (approximate total: 300 patients) who meet the inclusion criteria and then invited to complete the eCRF from each enrolled patient. Time to complete each eCRF will be 30 minutes, approximately.

In order to allow for a sufficiently long observational window, physicians will be asked to go back to a specific point in time, the index date, and sequentially select the medical records of the next 'n' patients who meet the inclusion criteria. The 'index date' will be defined as 30 days after the physician first prescribed palbociclib + partner therapy following the approval of the indication in Brazil (eg, if palbociclib + letrozole was available Feb 1, 2018 in Brazil and the physician initiated a patient on palbociclib+ letrozole the next day, the index date will be April 2, 2018).

The advantage to a retrospective medical record review approach over a database analysis is that of being designed specifically to collect data that fulfils the study objectives. Thus, it readily collects and informs on all key drug related clinical outcome measures of critical importance to this study, in a consistent manner, across countries if reported in a medical record. The resulting data set enables direct comparisons across markets, delivering in turn greater confidence in the reliability of conclusions drawn from the research. An additional advantage of this approach lies in the ability to obtain information that only the treating physician may be aware of, such as the reasons for treatment switches or discontinuations or more perceptive questions that rely on the physician's professional opinion.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: May 2, 2023
• Est. primary completion date: May 2, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• HR+/HER2- breast cancer diagnosis with confirmed ABC/MBC

• Received palbociclib as a first line therapy

• No prior or current enrolment in an interventional clinical trial for ABC/MBC

• Have a potential follow-up period of 6 months following the index date (30 days after first palbociclib prescription: palbociclib with fulvestrant and/or palbociclib with letrozole/aromatase inhibitor).

Exclusion Criteria:

• Patients who were enrolled to receive fulvestrant but already received previous therapies

Related Conditions & MeSH terms

• Breast Cancer
• Breast Carcinoma
• Breast Neoplasms

Locations

Country	Name	City	State
Brazil	Oncoclínicas Do Brasil Servicos Médicos S/A - Oncocentro	Belo Horizonte	Minas Gerais
Brazil	Hospital Sírio Libanês	Brasilia	Distrito Federal
Brazil	Instituto D´Or de Pesquisa E Ensino - Brasília	Brasilia	Distrito Federal
Brazil	Centro Especializado de Oncologia de Florianópolis	Florianópolis
Brazil	Hospital Araújo Jorge	Goiânia	Goiás
Brazil	Instituto de Mastologia e Oncologia	Goiânia
Brazil	Instituto D'or de Pesquisa e Ensino	Recife
Brazil	Centro de Tratamento de Tumores Botafogo	Rio de Janeiro
Brazil	Instituto D´or de Pesquisa e Ensino	Rio de Janeiro
Brazil	Instituto de Educação, Pesquisa e Gestão em Saúde	Rio de Janeiro
Brazil	Ensino E Terapia de Inovação Clínica Amo - Ética	Salvador	Bahia
Brazil	NOB - Nucleo de Oncologia da Bahia	Salvador	Bahia
Brazil	Hcor - Associação Beneficente Síria	São Paulo
Brazil	Hospital Paulistano - INSTITUTO DE EDUCAÇÃO, PESQUISA E GESTÃO EM SAÚDE	São Paulo

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Demographical characteristics of patients who have received palbociclib combination treatments in line with locally approved indications	30 days after the physician first prescribed palbociclib + partner therapy following the approval of the indication in Brazil . From when palbociclib + letrozole was available Feb 1, 2018 in Brazil and the physician initiated a patient on palbociclib+ letrozole until completion of this study in 2022.	30 days after prescribed palbociclib + partner therapy until completion of this study in 2022.
Primary	Adjuvant treatments received for subset of patients previously diagnosed with non-metastatic breast cancer who progressed to locally advanced (stage IIIB/C) or metastatic (stage IV) breast cancer.	30 days after the physician first prescribed palbociclib + partner therapy following the approval of the indication in Brazil . From when palbociclib + letrozole was available Feb 1, 2018 in Brazil and the physician initiated a patient on palbociclib+ letrozole until completion of this study in 2022.	30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Primary	Describe treatments received in the advanced/metastatic setting before palbociclib combination use	30 days after the physician first prescribed palbociclib + partner therapy following the approval of the indication in Brazil . From when palbociclib + letrozole was available Feb 1, 2018 in Brazil and the physician initiated a patient on palbociclib+ letrozole until completion of this study in 2022.	30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Primary	Describe treatments received in the advanced/metastatic setting after palbociclib combination use	30 days after the physician first prescribed palbociclib + partner therapy following the approval of the indication in Brazil . From when palbociclib + letrozole was available Feb 1, 2018 in Brazil and the physician initiated a patient on palbociclib+ letrozole until completion of this study in 2022.	30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Primary	Describe dosing associated with palbociclib use in clinical practice	30 days after the physician first prescribed palbociclib + partner therapy following the approval of the indication in Brazil . From when palbociclib + letrozole was available Feb 1, 2018 in Brazil and the physician initiated a patient on palbociclib+ letrozole until completion of this study in 2022.	30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Primary	Describe dose changes associated with palbociclib use in clinical practice	30 days after the physician first prescribed palbociclib + partner therapy following the approval of the indication in Brazil . From when palbociclib + letrozole was available Feb 1, 2018 in Brazil and the physician initiated a patient on palbociclib+ letrozole until completion of this study in 2022.	30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Primary	Describe interruptions associated with palbociclib use in clinical practice	30 days after the physician first prescribed palbociclib + partner therapy following the approval of the indication in Brazil . From when palbociclib + letrozole was available Feb 1, 2018 in Brazil and the physician initiated a patient on palbociclib+ letrozole until completion of this study in 2022.	30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Primary	Describe delays associated with palbociclib use in clinical practice	30 days after the physician first prescribed palbociclib + partner therapy following the approval of the indication in Brazil . From when palbociclib + letrozole was available Feb 1, 2018 in Brazil and the physician initiated a patient on palbociclib+ letrozole until completion of this study in 2022.	30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Primary	Describe discontinuations associated with palbociclib use in clinical practice	30 days after the physician first prescribed palbociclib + partner therapy following the approval of the indication in Brazil . From when palbociclib + letrozole was available Feb 1, 2018 in Brazil and the physician initiated a patient on palbociclib+ letrozole until completion of this study in 2022.	30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Primary	Describe supportive therapies received by patients while receiving palbociclib combination treatments	30 days after the physician first prescribed palbociclib + partner therapy following the approval of the indication in Brazil . From when palbociclib + letrozole was available Feb 1, 2018 in Brazil and the physician initiated a patient on palbociclib+ letrozole until completion of this study in 2022.	30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Primary	Proportion of patients who are progression free following clinical outcomes in overall population and defined subgroups for patients who had a potential follow-up of 6 months after palbociclib combination treatment initiation	30 days after the physician first prescribed palbociclib + partner therapy following the approval of the indication in Brazil . From when palbociclib + letrozole was available Feb 1, 2018 in Brazil and the physician initiated a patient on palbociclib+ letrozole until completion of this study in 2022.	30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Primary	Real world Objective response rate (ORR) following clinical outcomes in overall population and defined subgroups for patients who had a potential follow-up of 6 months after palbociclib combination treatment initiation	30 days after the physician first prescribed palbociclib + partner therapy following the approval of the indication in Brazil . From when palbociclib + letrozole was available Feb 1, 2018 in Brazil and the physician initiated a patient on palbociclib+ letrozole until completion of this study in 2022.	30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Primary	Proportion of patients alive following clinical outcomes in overall population and defined subgroups for patients who had a potential follow-up of 6 months after palbociclib combination treatment initiation	30 days after the physician first prescribed palbociclib + partner therapy following the approval of the indication in Brazil . From when palbociclib + letrozole was available Feb 1, 2018 in Brazil and the physician initiated a patient on palbociclib+ letrozole until completion of this study in 2022.	30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.

External Links

•   To obtain contact information for a study center near you, click here.